Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine and sleep quality after cesarean section
ChiCTR2600121620Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in Postpartum sleep disorder, anxiety disorder and major depressive disorder (MDD) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Incidence of postpartum sleep disturbance after cesarean delivery and Hospital Anxiety and Depression Scale (HADS) scores. Started Apr 2026; status: recruiting.
02
Drugs
esketamine
03
Conditions
Postpartum sleep disorderanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600121620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121620.